Market Research Logo

Global Parkinson’s Disease Market Report: 2016 Edition

Global Parkinson’s Disease Market Report: 2016 Edition

Parkinson’s Disease (PD) is a chronic and progressive neurodegenerative or movement disorder which involves the malfunction and death of vital nerve cells in the brain, called neurons. Parkinson’s primarily affects neurons in an area of the brain called the “substantia nigra”. The early signs and symptoms may be mild and may go unnoticed initially. The cause of this disease is mainly unknown with no cure till date but there exist several treatment options such as medications and surgery.

The current treatment market for Parkinson’s disease has several unmet needs as no treatment has yet been successful in fully restoring the function that produces dopamine. However, the treatment currently only aims at controlling and relieving symptoms. The Parkinson’s disease treatment market remains flooded by both branded and generic drugs. The market is expected to experience fluctuations in branded sales due to patent expiries and subsequent entry of generics in the market. Several biologics are under development for the treatment of Parkinson’s along with possibility of developing “Stem Cell” as a treatment therapy.

The Parkinson’s disease market is expected to acquire modest growth driven by launch of new therapies and increasing rate of drug treatment due to increasing healthcare expenditure and ageing population. The major growth drivers of the Parkinson’s disease market includes rising level of toxin exposure, increasing life expectancy, rising male population worldwide, ageing population, healthcare expenditure and pesticide consumption. However, the growth of the market will also remain challenged by generic erosion, current treatment limitations and increasing risk of developing Melanoma.

The report, “Global Parkinson’s disease Market” analyzes the currently prevailing condition of the market along with its future scope of development. The specific markets of the U.S., the European Union and Japan are being discussed in the report. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The major players in the industry are being profiled, along with their key financials and strategies for growth.


1. Market Overview
1.1 Introduction
1.2 Fundamental Features
1.3 Types of Parkinson’s Disease
1.4 Risk Factors
1.5 Treatment Options
Table A: Currently Leading Treatment Drugs for Parkinson’s Disease
Table B: Selected Late-Stage Drugs for Parkinson’s
2. Global Market
2.1 Global Parkinson’s Disease Drug Market by Value
Table 1: Global Parkinson’s Disease Drug Market by Value (2010-2015E)
2.1.1 Global Parkinson’s Disease Drug Market by Region
Table 2: Global Parkinson’s Disease Drug Market by Region (2014)
2.1.2 Global Parkinson’s Disease Market by Drug Class
Table 3: Global Parkinson’s Disease Market by Drug Class (2015E)
2.1.3 Global Parkinson’s Disease Patient Population by Severity
Table 4: Global Parkinson’s Disease Patient Population by Severity (2015E)
2.1.4 Global Parkinson’s Disease Patient Population by Region
Table 5: Global Parkinson’s Disease Patient Population by Region (2015E)
3. Regional Markets
3.1 The U.S.
3.1.1 The U.S. Parkinson’s Disease Market by Value & Volume
Table 6: The U.S. Parkinson’s Disease Market by Value & Volume (2013-2020E)
3.1.2 The U.S. Parkinson’s Disease Market Value by Category
Table 7: The U.S. Parkinson’s Disease Market Value by Category (2013-2017E)
3.1.3 The U.S. Parkinson’s Disease Market Volume by Category
Table 8: The U.S. Parkinson’s Disease Market Volume by Category (2015)
3.1.4 The U.S. Parkinson’s Disease Market by Drug Class
Table 9: The U.S. Parkinson’s Disease Market by Drug Class (2015)
3.1.5 The U.S. Parkinson’s Disease Branded Drugs Market
Table 10: The U.S. Parkinson’s Branded Drugs Market by Value & Volume (2013-2020E)
3.1.6 The U.S. Parkinson’s Disease Generic Drugs Market
Table 11: The U.S. Parkinson’s Generic Drugs Market by Value & Volume (2013-2020E)
3.2 The European Union
3.2.1 The E.U. Parkinson’s Patient Prevalence & Diagnosis
Table 12: The E.U. Parkinson’s Disease Prevalence and Diagnosis (2013-2018E)
3.2.2 The European Parkinson’s Disease Drug Market by Value
Table 13: The European* Parkinson’s Disease Drug Market by Value (2014/2015)
3.3 Japan
3.3.1 Japan’s Parkinson’s Disease Drug Market by Value
Table 14: Japan’s Parkinson’s Disease Drug Market by Value (2014/2015)
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Rising Level of Toxin Exposure
Table 15: Global Lead Production (2000-2014)
4.1.2 Rising Life Expectancy
Table 16: Global Life Expectancy at Birth (2008-2014E)
4.1.3 Rising Male Population
Table 17: Global Male Population (2009-2014)
4.1.4 Increasing Ageing Population
Table 18: Global Ageing Population above 65 Years (2009-2014)
4.1.5 Global Healthcare Expenditure
Table 19: Global Healthcare Expenditure (2009-2014)
4.1.6 Pesticides Consumption
4.2 Trends
4.2.1 Late-Stage Drug Development for Parkinson’s Disease
Table C: Selected Late-Stage Drugs for Parkinson’s Disease
4.2.2 Stem-Cell Therapy as Potential Treatment
4.2.3 Biologics under Development for Parkinson’s Disease
Table D: Biologics under Development for Parkinson’s Disease
4.3 Challenges
4.3.1 Generic Erosion
4.3.2 Parkinson’s Treatment associated with Higher Risk of Melanoma
4.3.3 Current Treatment Limitation
5. Competitive Landscape
5.1 The U.S. Parkinson’s Disease Branded Drug Market by Company
Table 20: The U.S Parkinson’s Disease Branded Market by Drug (2015)
5.2 The U.S. Parkinson’s Disease Generic Drug Market by Company
Table 21: The U.S. Parkinson’s Disease Generic Market by Drug (2015)
6. Company Profiles
6.1 Biotie Therapies Corp.
6.1.1 Business Overview
Table 22: Portfolio of Innovative CNS Medicines
6.1.2 Financial Overview
Table 23: Biotie Therapies Corp Revenue & Net Income/Loss (2011-2015)
6.1.3 Business Strategies
Table 24: Biotie’s Research and Development Expenditure (2011-2015)
6.2 Adamas Pharmaceuticals Inc.
6.2.1 Business Overview
Table E: Adamas Pharmaceuticals Therapeutic Portfolio
6.2.2 Financial Overview
Table 25: Adamas Pharmaceuticals Revenue and Net Income/Loss (2012-2015)
6.2.3 Business Strategies
Table 26: Adamas Pharmaceutical’s R&D Expenditure (2012-2015)
6.3 Lundbeck
6.3.1 Business Overview
Table 27: Lundbeck’s Revenue Share by Product (2014)
Table 28: Lundbeck’s Revenue Share by Region (2014)
6.3.2 Financial Overview
Table 29: Lundbeck’s Revenue and Annual Growth (2012-2017E)
6.3.3 Business Strategies
Table F: Lundbeck’s Product Pipeline
6.4 Novartis
6.4.1 Business Overview
Table 30: Novartis Revenue by Business Segments (2015)
6.4.2 Financial Overview
Table 31: Novartis Revenue and Net Income (2011-2015)
6.4.3 Business Strategies
7. Market Outlook
7.1 Global Market Forecast
Table 32: Global Parkinson’s Disease Market Forecast (2013-2017F)
7.2 Forecast Methodology
Table G: Dependent and Independent Variable
7.2.1 Dependent and Independent Variables
7.2.2 Correlation Analysis
Table H: Correlation Matrix
7.2.3 Regression Analysis
Table I: Model Summary – Coefficient of Determination

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report